ECTRIMS 2022 | Impacts of polypharmacy on MS patients’ outcomes

Anibal Chertcoff, MD, PhD, The University of British Columbia, Vancouver, Canada, describes the effect of polypharmacy on the outcomes of patients with multiple sclerosis (MS) In a complementary analysis of a population-based study evaluating the prevalence of polypharmacy in people with MS, it was observed that the hospitalization risk doubled in MS patients exposed to polypharmacy compared with those not exposed to polypharmacy. In addition, the multiple sclerosis patients exposed to polypharmacy had an increased frequency of adverse drug reactions Several studies in the general and elderly population have shown that polypharmacy is associated with increased mortality risk. In the future, it will be interesting to carry out similar studies in the MS population, particularly in older adults with MS. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.